<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4F8CB53C-C173-40A5-8831-B19670EA9A6C"><gtr:id>4F8CB53C-C173-40A5-8831-B19670EA9A6C</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Tomasec</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C7C0FC1F-2464-4404-9921-CAFD2EB08C64"><gtr:id>C7C0FC1F-2464-4404-9921-CAFD2EB08C64</gtr:id><gtr:firstName>Eddie</gtr:firstName><gtr:otherNames>Chung</gtr:otherNames><gtr:surname>Wang</gtr:surname><gtr:orcidId>0000-0002-2243-4964</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D05D7386-7173-4E4C-94C6-B52EDAA849C2"><gtr:id>D05D7386-7173-4E4C-94C6-B52EDAA849C2</gtr:id><gtr:firstName>Gavin</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Wilkinson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0700142"><gtr:id>1C94A332-B8E4-49AB-BB3A-57CE14D061CD</gtr:id><gtr:title>Modulation of Natural Killer Cell By Human Cytomegalovirus</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700142</gtr:grantReference><gtr:abstractText>Cytomegalovirus (CMV) is related to the herpes virus that causes cold sores. Like herpes, CMV is carried for life and can reactivate at any time to cause disease. Most people worldwide are infected with CMV, yet do not know. However, in hospitals, CMV is well known and a major problem. CMV can cause severe multi-organ disease in individuals whose immune system has been compromised by infections (e.g. HIV AIDS), suppressed by drugs (for bone marrow, heart or kidney transplants) and also when it infects unborn children in the womb. CMV is the most complex of any human virus with 167 genes. What do they all do? Surprisingly, most of are not needed by virus to grow, rather they may be there to attack our immune system. 

Natural Killers (NK) cells are crucial in fighting infections (CMV in particular) and cancers. NK cells detect signals on the surface cells that indicate whether things are OK or not. If they are not, NK cells are fierce ? rapidly both killing the problem cell and triggering the immune system to respond. Only recently have we begun to understand what signals NK cells are responding to ? and there are many. Surprisingly, CMV has helped tell us how NK cells work.

Eight CMV genes have been identified that prevent NK cells from killing. These CMV genes affect the expression of cellular proteins recognised by NK cells. Our laboratory has been heavily involved in this work. Because HCMV has an enormous genome, finding these genes is been tough. We know the virus encodes many more NK evasion functions, although not how many. Over the past 5 years, we have worked hard to develop a hyper-efficient system to screen the whole genome, and now this system is ready. 

We want to identify and characterise as many NK evasion genes as possible. How these genes work, will tell us how NK cells work. There is also good evidence in a mouse model that these genes are essential for the virus to cause disease. With scientists in the US, we intend to determine whether this is true in primates. This study is important to understanding how CMV causes disease. However, by identifying and knocking these NK evasion genes out of the virus, it may yet be possible to develop a CMV vaccine.</gtr:abstractText><gtr:technicalSummary>Human cytomegalovirus (HCMV) has the largest genome (~236Kb) of any characterised human virus encoding 167 putative open reading frames (ORFs). Although this pathogen is carried by majority of the world?s population, the much of the HCMV genome remains uncharacterised. The complexity of the genome makes the mapping of even recognised viral functions to specific HCMV genes extremely problematical. Natural Killer (NK) cells are crucial in controlling cytomegalovirus infections. A substantial proportion of the HCMV genome acts to suppress NK recognition; to date eight HCMV NK evasion functions have been characterised even though only a fraction of the genome has been sampled. We propose exploiting DNA recombineering technology to generate a bank of 167 replication-deficient adenovirus (Ad) vectors each encoding a discrete, epitope-tagged HCMV ORF. Both Ad recombinants and HCMV proteins expressed in a prokaryotic system will be used to generate specific antibodies to support expression studies. A compete HCMV gene bank of Ad recombinants will be an invaluable resource for the HCMV research community. Our specific goal is to perform functional NK assays, using CD107 mobilisation and intracellular interferon-gamma staining, to identify HCMV gene function capable of promoting and suppressing NK recognition. Constructs encoding rhesus CMV homologues of HCMV NK evasion functions will also be evaluated to facilitate studies in the closest tractable in vivo model for HCMV.</gtr:technicalSummary><gtr:fund><gtr:end>2010-11-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>563340</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Virology Unit</gtr:department><gtr:description>Investigations into HCMV gene usage</gtr:description><gtr:id>90F051A2-5D37-4E11-8F0D-76835BB4FAD3</gtr:id><gtr:impact>Wilkinson G.W., Tomasec P., Stanton R.J., Armstrong, M., Prod'homme, V., Aicheler, R., McSharry, B.P., Rickards, C.R., Cochrane, D., Llewellyn-Lacey, S., Wang, E.C., Griffin, C.A. and Davison, A.J. (2008). Modulation of natural killer cells by human cytomegalovirus. J. Clin. Virol. 41, 206-12. 
Bradley, A.J., Kovacs, I.J., Gatherer, D., Dargan, D.J., Alkharsah, K.R., Chan, P.K., Carman, W.F., Dedicoat, M., Emery, V.C., Geddes, C.C., Gerna, G., Ben-Ismaeil, B., Kaye, S., McGregor, A., Moss, P.A., Pusztai, R., Rawlinson, W.D., Scott, G.M., Wilkinson, G.W., Schulz, T.F. and Davison, A.J. (2008). Genotypic analysis of two hypervariable human cytomegalovirus genes. J. Med. Virol. 80, 1615-23. 
Bradley, A. J., N. S. Lurain, P. Ghazal, U. Trivedi, C. Cunningham, K. Baluchova, D. Gatherer, G. W. Wilkinson, D. J. Dargan, and A. J. Davison. 2009. High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. J Gen Virol. 90, 2375-80. 
Cunningham, C., D. Gatherer, B. Hilfrich, K. Baluchova, D. J. Dargan, M. Thomson, P. D. Griffiths, G. W. Wilkinson, T. F. Schulz, and A. J. Davison. 2009. Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens. J Gen Virol. 91, 605-15.
Stanton, R.J, Baluchova, K, Dargan, D.J., Cunningham, C., Sheehy, O, Seirafian, S., McSharry, B.P., Neale, M.L., Davies, J.A., Tomasec, P., Davison, A.J. and Wilkinson, G.W.G. (2010). Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication. J. Clin Invest. 120, 3191-208</gtr:impact><gtr:partnerContribution>There has been a major problem in the HCMV field. The virus genome degenerates whenever it is propagated in vitro. Consequently, the gene content of HCMV genome was ill-defined. We have addressed this issue together. HCMV strain Merlin, a Cardiff isolate, was sequenced and annotated by Dr Davison's group in Glasgow. HCMV strain Merlin proved the first complete sequence of an HCMV clinical isolate, and consequently became the prototype strain on GenBank. In followup studies a number of additional HCMV clinical isolates have been sequenced. Such analyses it has been revealed that a number of HCMV genes are hypervariable, RL13 and UL128 locus mutate in cell culture and that some viruses present in clinical isolates have mutant genes. We cloned the complete genome of strain Merlin in a bacterial artificial chromosome (BAC). Defect that had arisen by minimal passage in vitro were identified and corrected by reference to the original clinical sample. For HCMV to replicate efficiently in human fibroblasts it has two acquire mutations in two loci. We are in the process of characterising the RL13 gene in collaboration with Dr Davison's laboratory. A basic understanding of HCMV gene usage has been crucial for our studies of virus gene function.</gtr:partnerContribution><gtr:piContribution>We have provided HCMV clinical isolates, HCMV BAC vector and Ad recombinants to assist in studies in Glasgow. We have hosted a researcher in our laboratory to facilitate technology transfer.</gtr:piContribution><gtr:sector>Public</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC I3-IRG PhD Studentship</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>296877A5-85BF-4A20-AAB2-A091A2E8EF08</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Mrs John Nixon Scholarship (PhD studentship)</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Cardiff University</gtr:fundingOrg><gtr:id>70D4F666-074A-42F2-869A-6A444CBA4FFB</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>445567</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>E737AB6F-7E84-4BF3-B6D9-785FBCA0C056</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1062032</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme Grant</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>WT090323</gtr:fundingRef><gtr:id>25DB845C-A9F7-4B4B-9A9C-8830D19FA392</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Adenovirus vectors encoding nearly all HCMV open reading frames have been generated</gtr:description><gtr:id>B7AA041C-BF2A-4BB9-9014-21CCAD824E39</gtr:id><gtr:impact>We have characterised the expression of nearly all ORFs RL1-UL46. We have identified 4 candidate NK modulatory functions.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Adenovirus Vector Bank of HCMV ORFs</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B246F54A-3681-4176-B9D8-1FFC66498AFB"><gtr:id>B246F54A-3681-4176-B9D8-1FFC66498AFB</gtr:id><gtr:title>Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function.</gtr:title><gtr:parentPublicationTitle>BioTechniques</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b6d1b84696df7259b815e773b8f7237"><gtr:id>3b6d1b84696df7259b815e773b8f7237</gtr:id><gtr:otherNames>Stanton RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0736-6205</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B73ABD58-E8DF-4DBC-9465-694C1B045BE4"><gtr:id>B73ABD58-E8DF-4DBC-9465-694C1B045BE4</gtr:id><gtr:title>Neutrophils recruited by IL-22 in peripheral tissues function as TRAIL-dependent antiviral effectors against MCMV.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/766b9ac2fc7a6a74db1e0376e5a80d08"><gtr:id>766b9ac2fc7a6a74db1e0376e5a80d08</gtr:id><gtr:otherNames>Stacey MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AFE15294-BCCC-4C55-99A4-DA80FD5D214A"><gtr:id>AFE15294-BCCC-4C55-99A4-DA80FD5D214A</gtr:id><gtr:title>Human cytomegalovirus suppresses Fas expression and function.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f7b31ea2a956b96ea90c70b102d649fa"><gtr:id>f7b31ea2a956b96ea90c70b102d649fa</gtr:id><gtr:otherNames>Seirafian S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1B8771B3-B9D7-4C19-9E4F-D91911CC41F8"><gtr:id>1B8771B3-B9D7-4C19-9E4F-D91911CC41F8</gtr:id><gtr:title>Reconstruction of the complete human cytomegalovirus genome in a BAC reveals RL13 to be a potent inhibitor of replication.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b6d1b84696df7259b815e773b8f7237"><gtr:id>3b6d1b84696df7259b815e773b8f7237</gtr:id><gtr:otherNames>Stanton RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6499298F-10BE-423A-98E1-1B70FC46D74E"><gtr:id>6499298F-10BE-423A-98E1-1B70FC46D74E</gtr:id><gtr:title>High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8bbb042f8d7ccc54a641714a6222f8a7"><gtr:id>8bbb042f8d7ccc54a641714a6222f8a7</gtr:id><gtr:otherNames>Bradley AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3C3F6AB6-CC20-406A-ABB3-A872AA02F25B"><gtr:id>3C3F6AB6-CC20-406A-ABB3-A872AA02F25B</gtr:id><gtr:title>Differential relocation and stability of PML-body components during productive human cytomegalovirus infection: detailed characterization by live-cell imaging.</gtr:title><gtr:parentPublicationTitle>European journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6ad757638bf6e6a427110748ca55cff7"><gtr:id>6ad757638bf6e6a427110748ca55cff7</gtr:id><gtr:otherNames>Dimitropoulou P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0171-9335</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/40AC6C7E-D699-424E-9ABF-36C74A386FC7"><gtr:id>40AC6C7E-D699-424E-9ABF-36C74A386FC7</gtr:id><gtr:title>Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/89314afe407ab0f79cf15f9d0f030d85"><gtr:id>89314afe407ab0f79cf15f9d0f030d85</gtr:id><gtr:otherNames>Smith W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/16A1936F-8C7F-4556-80F1-C5D7D8BCC8BA"><gtr:id>16A1936F-8C7F-4556-80F1-C5D7D8BCC8BA</gtr:id><gtr:title>Human cytomegalovirus: taking the strain.</gtr:title><gtr:parentPublicationTitle>Medical microbiology and immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d8a2735a3ab0c4d75ed431e7759769ce"><gtr:id>d8a2735a3ab0c4d75ed431e7759769ce</gtr:id><gtr:otherNames>Wilkinson GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-8584</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CAEFA5BF-8971-45D6-9CB0-56780CE1BA1A"><gtr:id>CAEFA5BF-8971-45D6-9CB0-56780CE1BA1A</gtr:id><gtr:title>HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b6d1b84696df7259b815e773b8f7237"><gtr:id>3b6d1b84696df7259b815e773b8f7237</gtr:id><gtr:otherNames>Stanton RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/85815773-9998-474A-8E07-DBC357F0470D"><gtr:id>85815773-9998-474A-8E07-DBC357F0470D</gtr:id><gtr:title>Cytomegaloviruses from Molecular Pathogenesis to Intervention</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e76607836ae45b6e42b6c4a282ecd342"><gtr:id>e76607836ae45b6e42b6c4a282ecd342</gtr:id><gtr:otherNames>Wilkinson, GW, Aicheler, R.J. and Wang, E.C.Y.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/377D4A05-AC80-495F-AB45-9969D45CE18A"><gtr:id>377D4A05-AC80-495F-AB45-9969D45CE18A</gtr:id><gtr:title>Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/58e38151138fdd15af992c15175ac172"><gtr:id>58e38151138fdd15af992c15175ac172</gtr:id><gtr:otherNames>Prod'homme V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AA5E4FEF-1E99-4127-8D6A-C537125B77FC"><gtr:id>AA5E4FEF-1E99-4127-8D6A-C537125B77FC</gtr:id><gtr:title>Cytomegalovirus destruction of focal adhesions revealed in a high-throughput Western blot analysis of cellular protein expression.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3b6d1b84696df7259b815e773b8f7237"><gtr:id>3b6d1b84696df7259b815e773b8f7237</gtr:id><gtr:otherNames>Stanton RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E1C14213-B1AA-4E57-BAC5-A461128C2F12"><gtr:id>E1C14213-B1AA-4E57-BAC5-A461128C2F12</gtr:id><gtr:title>Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b26aab7afcc879892b3815a7693dac5"><gtr:id>1b26aab7afcc879892b3815a7693dac5</gtr:id><gtr:otherNames>Dargan DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7BB4FE58-25F8-4AD8-B6F4-D289A1886140"><gtr:id>7BB4FE58-25F8-4AD8-B6F4-D289A1886140</gtr:id><gtr:title>Modulation of natural killer cells by human cytomegalovirus.</gtr:title><gtr:parentPublicationTitle>Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d8a2735a3ab0c4d75ed431e7759769ce"><gtr:id>d8a2735a3ab0c4d75ed431e7759769ce</gtr:id><gtr:otherNames>Wilkinson GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1386-6532</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8CFD08DA-7B42-4691-B75C-4669B26E44E6"><gtr:id>8CFD08DA-7B42-4691-B75C-4669B26E44E6</gtr:id><gtr:title>Complex I binding by a virally encoded RNA regulates mitochondria-induced cell death.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6f1fa95512c8c24498210be8597cb0d8"><gtr:id>6f1fa95512c8c24498210be8597cb0d8</gtr:id><gtr:otherNames>Reeves MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/640986C4-F708-4916-98CA-DBCF2EC878ED"><gtr:id>640986C4-F708-4916-98CA-DBCF2EC878ED</gtr:id><gtr:title>The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-1+ but activates LIR-1- NK cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/58e38151138fdd15af992c15175ac172"><gtr:id>58e38151138fdd15af992c15175ac172</gtr:id><gtr:otherNames>Prod'homme V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/65F2FCEE-48C9-42DD-A933-0F704E997F41"><gtr:id>65F2FCEE-48C9-42DD-A933-0F704E997F41</gtr:id><gtr:title>Adenovirus E3/19K promotes evasion of NK cell recognition by intracellular sequestration of the NKG2D ligands major histocompatibility complex class I chain-related proteins A and B.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c345338015db5b28ee186446ac270dc0"><gtr:id>c345338015db5b28ee186446ac270dc0</gtr:id><gtr:otherNames>McSharry BP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DA90CC64-4789-4693-A397-634DC5BC5BB6"><gtr:id>DA90CC64-4789-4693-A397-634DC5BC5BB6</gtr:id><gtr:title>The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d7404c9ae8e2c662f4f25c5bfd1c6a84"><gtr:id>d7404c9ae8e2c662f4f25c5bfd1c6a84</gtr:id><gtr:otherNames>McLaren JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8A613BE6-D3C8-490F-9476-348EE3852E03"><gtr:id>8A613BE6-D3C8-490F-9476-348EE3852E03</gtr:id><gtr:title>The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties.</gtr:title><gtr:parentPublicationTitle>Antiviral chemistry &amp; chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d70f79ddb10659f4b9e446ebaf2d628"><gtr:id>4d70f79ddb10659f4b9e446ebaf2d628</gtr:id><gtr:otherNames>Holcakova J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0956-3202</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9408EB2B-BE9D-4E68-8ED8-257DE5FAF2A9"><gtr:id>9408EB2B-BE9D-4E68-8ED8-257DE5FAF2A9</gtr:id><gtr:title>Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/375e20070a4cab507c3b015aba01aebf"><gtr:id>375e20070a4cab507c3b015aba01aebf</gtr:id><gtr:otherNames>Cunningham C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B08908CD-D6D9-478B-9E2B-085D6DF1F0C4"><gtr:id>B08908CD-D6D9-478B-9E2B-085D6DF1F0C4</gtr:id><gtr:title>Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b4f409f250b4b1959242bf8c5770b4e4"><gtr:id>b4f409f250b4b1959242bf8c5770b4e4</gtr:id><gtr:otherNames>Clark SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FDD866B2-7DFF-4448-B7B8-A62EBBC361BF"><gtr:id>FDD866B2-7DFF-4448-B7B8-A62EBBC361BF</gtr:id><gtr:title>Adenovirus vector delivery stimulates natural killer cell recognition.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4ab6b817c8e9b654853c81fa652b9c62"><gtr:id>4ab6b817c8e9b654853c81fa652b9c62</gtr:id><gtr:otherNames>Tomasec P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F2748689-EEFD-4016-AD83-41D4296B7845"><gtr:id>F2748689-EEFD-4016-AD83-41D4296B7845</gtr:id><gtr:title>Inhibition of post-transcriptional RNA processing by CDK inhibitors and its implication in anti-viral therapy.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d70f79ddb10659f4b9e446ebaf2d628"><gtr:id>4d70f79ddb10659f4b9e446ebaf2d628</gtr:id><gtr:otherNames>Holcakova J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/838F8B1B-D6CB-41E4-AA3E-043EB90FFAC8"><gtr:id>838F8B1B-D6CB-41E4-AA3E-043EB90FFAC8</gtr:id><gtr:title>Two novel human cytomegalovirus NK cell evasion functions target MICA for lysosomal degradation.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4db494963f9a272576ab42849a536cb6"><gtr:id>4db494963f9a272576ab42849a536cb6</gtr:id><gtr:otherNames>Fielding CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B4A546C2-8094-4F24-B0E0-E071BF7C5D0B"><gtr:id>B4A546C2-8094-4F24-B0E0-E071BF7C5D0B</gtr:id><gtr:title>Differential requirements of the C terminus of Nbs1 in suppressing adenovirus DNA replication and promoting concatemer formation.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/196a164f6d8093c0353dfd5f05173a96"><gtr:id>196a164f6d8093c0353dfd5f05173a96</gtr:id><gtr:otherNames>Lakdawala SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7AEED321-5673-4221-859B-6887F76946BE"><gtr:id>7AEED321-5673-4221-859B-6887F76946BE</gtr:id><gtr:title>Genotypic analysis of two hypervariable human cytomegalovirus genes.</gtr:title><gtr:parentPublicationTitle>Journal of medical virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8bbb042f8d7ccc54a641714a6222f8a7"><gtr:id>8bbb042f8d7ccc54a641714a6222f8a7</gtr:id><gtr:otherNames>Bradley AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0146-6615</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/529BD333-5C7A-4DB0-B644-021B833BCB4E"><gtr:id>529BD333-5C7A-4DB0-B644-021B833BCB4E</gtr:id><gtr:title>Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d6bff84453c6406fcdb0850cfbe2d8d8"><gtr:id>d6bff84453c6406fcdb0850cfbe2d8d8</gtr:id><gtr:otherNames>Hsu JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700142</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>